{"id":"ts-1-oxaliplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hand-foot syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TS-1 (tegafur/gimeracil/oteracil potassium) is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase, disrupting nucleotide synthesis and DNA replication. Oxaliplatin is a third-generation platinum compound that forms interstrand and intrastrand DNA crosslinks, preventing DNA unwinding and replication. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"TS-1 is a combination chemotherapy regimen that inhibits thymidylate synthase and DNA synthesis, while oxaliplatin is a platinum-based agent that forms DNA crosslinks to kill cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:00.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer (advanced or metastatic)"},{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT03382600","phase":"PHASE2","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-03-26","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT04999332","phase":"PHASE2","title":"Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2021-12-10","conditions":"Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemotherapy","enrollment":58},{"nctId":"NCT03726021","phase":"PHASE2","title":"Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Qingdao Central Hospital","startDate":"2018-01-26","conditions":"Overall Survival","enrollment":47},{"nctId":"NCT02191566","phase":"PHASE2","title":"S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy","status":"TERMINATED","sponsor":"Kangbuk Samsung Hospital","startDate":"2015-05","conditions":"Stomach Cancer","enrollment":8},{"nctId":"NCT01761461","phase":"PHASE3","title":"Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2013-02-06","conditions":"Gastric Cancer","enrollment":547},{"nctId":"NCT02301481","phase":"PHASE2","title":"A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2014-01","conditions":"Stomach Neoplasms, Neoadjuvant Therapy, Chemoradiotherapy","enrollment":71},{"nctId":"NCT01283204","phase":"PHASE2","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03-09","conditions":"Recurrent or Metastatic Gastric Cancer","enrollment":180},{"nctId":"NCT03316326","phase":"PHASE2","title":"S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-11-01","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":35},{"nctId":"NCT02527785","phase":"PHASE2","title":"Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2015-02","conditions":"Stomach Neoplasm","enrollment":44},{"nctId":"NCT02527824","phase":"PHASE2","title":"Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2015-03","conditions":"Biliary Tract Neoplasm","enrollment":31},{"nctId":"NCT01472250","phase":"","title":"A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China","status":"COMPLETED","sponsor":"Peking University","startDate":"2011-11","conditions":"Advanced Gastric Cancer","enrollment":498},{"nctId":"NCT02870153","phase":"PHASE2","title":"SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer","status":"UNKNOWN","sponsor":"The First People's Hospital of Changzhou","startDate":"2013-01","conditions":"Colorectal Neoplasm","enrollment":60},{"nctId":"NCT01100801","phase":"PHASE2","title":"A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2010-07","conditions":"Recurrent Gastric Cancer","enrollment":90},{"nctId":"NCT01542294","phase":"PHASE1, PHASE2","title":"SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-06","conditions":"Gastric Cancer","enrollment":71},{"nctId":"NCT01693445","phase":"PHASE1","title":"S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2012-06","conditions":"Gastrointestinal Neoplasms","enrollment":22},{"nctId":"NCT01671449","phase":"PHASE3","title":"S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Min-Hee Ryu","startDate":"2012-12","conditions":"Gastric Cancer","enrollment":338},{"nctId":"NCT01679340","phase":"PHASE2","title":"A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery","status":"UNKNOWN","sponsor":"Peking University","startDate":"2011-04","conditions":"Gastric Cancer","enrollment":160},{"nctId":"NCT01531452","phase":"PHASE2","title":"The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-06","conditions":"Stomach Neoplasms","enrollment":43},{"nctId":"NCT00527930","phase":"PHASE2","title":"Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2007-09","conditions":"Breast Neoplasms","enrollment":87},{"nctId":"NCT00677144","phase":"PHASE2","title":"Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2008-04","conditions":"Colorectal Neoplasm","enrollment":88},{"nctId":"NCT00525005","phase":"PHASE2","title":"Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2007-08","conditions":"Stomach Neoplasms","enrollment":44},{"nctId":"NCT01608646","phase":"PHASE2","title":"Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2012-03","conditions":"Gastrointestinal Cancer","enrollment":200},{"nctId":"NCT01429961","phase":"PHASE2","title":"Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2011-05","conditions":"Advanced Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT00512681","phase":"PHASE2","title":"A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2007-07","conditions":"Stomach Neoplasms","enrollment":44},{"nctId":"NCT00961077","phase":"PHASE2","title":"Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Soonchunhyang University Hospital","startDate":"2009-08","conditions":"Elderly, S-1, Oxaliplatin","enrollment":36},{"nctId":"NCT00531245","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2006-08","conditions":"Colorectal Neoplasms","enrollment":77},{"nctId":"NCT00316745","phase":"PHASE3","title":"IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer","status":"SUSPENDED","sponsor":"Hokkaido Gastrointestinal Cancer Study Group","startDate":"2006-04","conditions":"Metastatic Colorectal Cancer","enrollment":200},{"nctId":"NCT00506571","phase":"PHASE2","title":"Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2007-07","conditions":"Colorecal Neoplasms, Secondary","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TS-1, oxaliplatin","genericName":"TS-1, oxaliplatin","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TS-1 is a chemotherapy drug used to treat stomach and colorectal cancers, including advanced gastric cancer and recurrent gastric cancer. As a small molecule DNA inhibitor, TS-1 works by inhibiting DNA, a mechanism similar to that of oxaliplatin, another chemotherapy drug.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}